A Trinity College Dublin spin-out, Opsona Therapeutics, has received a 33m fund to aid the developemnt of one of its drugs. The drug, OPN-305, which protects the body from rejection of donor kidneys is set to undergo a Phase II clinical trial in the following months where its tolerability, efficacy and safety will be tested.